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Screening for diabetes
Targeted screening causes less stress than mass screening, but there is 
insufficient evidence to advocate either
In this week’s BMJ, two studies by Eborall and colleagues 
assess the psychological impact of screening for diabetes 
mellitus in primary care.1 2 Screening for diabetes is pri-
marily aimed at preventing cardiovascular disease. The 
risk of cardiovascular disease increases proportionally 
as concentrations of glucose increase, with no thresh-
old below which the risk remains constant.3 This is in 
contrast with other complications of diabetes—such as 
retinopathy, neuropathy, and nephropathy—the risk of 
which sharply increases when glucose concentrations 
exceed the threshold of 11 mmol/l. At this concentra-
tion the typical diagnostic signs of diabetes are usually 
present—thirst, polyuria, and weight loss. 
Population based mass screening for diabetes has 
been proposed for several years.4 This has been fuelled 
by rising plasma glucose concentrations in most popula-
tions worldwide, as a result of increasing body weight 
associated with a more sedentary lifestyle and changes 
in diet. Arguments for mass screening include the fact 
that mildly increased plasma glucose does not cause 
symptoms and usually persists for several years, it can be 
determined by a capillary drop of blood, and it is associ-
ated with increased risk of cardiovascular disease.5 
However, two questions need to be resolved before 
screening can be recommended. Firstly, will treating 
asymptomatic hyperglycaemia help prevent cardiovas-
cular disease? Secondly, what psychological harm could 
be caused by anxiety regarding the screening result or 
the effects of a diagnosis that requires changes in diet 
and activity patterns and lifelong use of drugs?6 The first 
question should be answered by the ongoing interna-
tional ADDITION trial into the effectiveness of multi-
factorial treatment for cardiovascular disease in people 
with screen detected diabetes.7
The two studies in this week’s issue look at the second 
question, at least in white British people. Eborall and 
colleagues studied the psychological effects of stepwise 
screening programme for diabetes conducted within the 
Cambridge arm of the ADDITION trial. They found 
no changes in anxiety, depression, or worries about dia-
betes between the invitation for the first screening visit 
and a year after completing the programme.1 Moreover, 
the results did not differ significantly between people 
invited for screening and those who were not invited.
The authors also conducted a smaller qualitative 
study within the Cambridge ADDITION study at sev-
eral time points during the stepwise screening process.2 
Participants seemed to adapt their feelings about the 
possibility of having a chronic disease with each step 
in the screening process, thereby controlling the psy-
chological burden.2 Both studies were hampered by a 
low response rate, which is probably not random. If 
people who were anxious about examinations, forms, 
and medical or research staff preferentially chose not to 
participate, a psychological harm of screening would 
be masked by selection bias. However, this is unlikely 
because the results are in line with the absence of 
psychological effects of blood pressure screening8 
and with a smaller study in the Dutch part of the 
ADDITION trial.9
It is important to realise that the ADDITION study 
consisted of a stepwise screening procedure. Only peo-
ple with an increased risk of diabetes—on the basis of a 
raised cardiovascular risk known to their general prac-
titioner—were invited for the first examination. They 
had probably been counselled about their weight or 
were aware of their increased risk of cardiovascular 
disease because they had been prescribed drugs to 
lower their blood pressure. As Eborall and colleagues 
suggest,2 this might explain the limited psychological 
stress of the screening procedure and a diagnosis of 
diabetes—people were already aware of their high risk 
before the invitation for screening. Harmful psychologi-
cal effects are more likely to occur in population based 
mass screening, where everybody within a certain age 
range is invited for a plasma glucose measurement (like 
breast cancer screening). In that situation, the stepwise 
approach is replaced by one large leap from feeling 
completely healthy to harsh lifestyle changes and life-
long use of drugs.
Targeted screening for diabetes, also referred to as 
case finding or opportunistic screening, means that 
health professionals measure glucose in people with 
a presumed increased risk of diabetes. Eborall and 
colleagues’ results further tip the balance in favour of 
individual targeted screening over mass population 
screening for diabetes. Screening and diagnosis within 
the healthcare setting enables individually tailored 
 follow-up and treatment.
As Eborall and colleagues have shown such a stepwise 
approach may be important to minimise psychological 
stress.2 Targeted screening is also more cost effective 
than population screening.10 
Nevertheless, even though targeted screening may 
not increase psychological stress we still need to show 
that treating asymptomatic people with slightly raised 
glucose concentrations is effective. At the moment there 
is insufficient evidence to recommend screening for 
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Self management of type 2 diabetes
More efforts are needed to capture the patients’ perspective
The introduction of home blood glucose monitoring in 
the late 1970s was instrumental in shifting the focus of 
the management of diabetes from doctors to patients.1 
It is now a common view that patients are primarily 
responsible for the daily management of their diabe-
tes, which includes self monitoring, at least in patients 
treated with insulin. The usefulness of self monitoring 
in patients with type 2 diabetes not treated with insulin 
is controversial, a debate that was recently fuelled by 
findings from the DIGEM trial.2
Two studies in this week’s BMJ are related to opti-
mising the treatment of type 2 diabetes.3 4 In the first, 
Peel and colleagues3 report the results from a longi-
tudinal qualitative study of the views of patients with 
type 2 diabetes about self monitoring, using a repeat 
interview design. The authors rightly point out that the 
patient’s view has been largely absent in discussions on 
self monitoring in type 2 diabetes. While self testing of 
blood glucose has the potential to empower patients, it 
is often viewed as complex and inconvenient. Finger 
pricks can be painful, and the repeated confrontation 
with unexpected outcomes and “bad” results can lead 
to frustration, guilt, and indeed “learned helplessness.”5 6 
These negative effects on patients’ wellbeing are prob-
ably responsible to a large extent for the low adherence 
to self monitoring seen in patients with both type 1 and 
type 2 diabetes.7
Peel and colleagues previously reported from the 
same research project on patients views on self moni-
toring six months after diagnosis.8 Results suggested 
that patients with poorly controlled diabetes were more 
likely than those with good control to voice concerns 
and to have problems with self monitoring.
Three years after diagnosis, 18 of these patients (one 
on insulin) who had ever self monitored their blood 
glucose were contacted for a third interview round, 
to explore (changes in) their experiences and views 
of self monitoring.3 The relevance of a longitudinal 
approach is underscored by recent research showing 
that self monitoring practices change over time and may 
have different effects on glycaemic control in new and 
established users.9 Peel and colleagues found that fewer 
patients were self monitoring over time, and those who 
did continue monitoring did so less frequently. Some 
patients expressed uncertainty about the meaning of the 
test results and how to act on them, while others found 
self monitoring to be reassuring and did it routinely. 
Most participants voiced concerns about the value 
health professionals placed on their readings. Doctors 
generally appeared to show little interest in patients’ 
test results after the initial phase, leading some patients 
to perceive self monitoring as not very important or 
even pointless. Interestingly, some patients continued to 
self monitor despite lack of guidance and the perceived 
health professionals’ disinterest.
The generalisability of the findings from this small 
qualitative study remains uncertain, although the 
reported experiences and attitudes seem all too realistic 
and common. The study reminds us of the importance 
of demographic, social, and psychological variables 
in explaining the observed interindividual differ-
ences. The question of how useful self monitoring is 
in patients not being treated with insulin remains, but 
clearly Peel and colleagues’ study confirms the need to 
develop educational strategies that can help patients 
effectively use blood glucose monitoring and manage 
negative feedback. As the authors point out, self moni-
toring is apparently still surrounded with feelings of 
personal failure and self blame, particularly in female 
patients. Experience has shown that simply providing 
patients with a manual on how to overcome common 
emotional and behavioural barriers to self testing can 
have significant beneficial effects on psychology and 
glycaemic control.10 The second study, a systematic 
review by Eurich and colleagues, assesses the optimum 
drug treatment for patients with type 2 diabetes and 
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diabetes, and until the results of the ADDITION trial 
are known we will have to wait until people present 
with the classic symptoms of thirst and polyuria before 
 screening them.
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heart failure.4 The review used evidence from eight 
studies to look at the effects of various blood glucose 
lowering drugs, including oral drugs and insulin, on 
morbidity and mortality in patients with type 2 dia-
betes and heart failure. It found that metformin is 
the only antidiabetic drug that is not associated with 
any measurable harm in people with diabetes and 
heart failure. In fact, metformin was associated with 
reduced mortality.
A weakness of the review is that most of the data 
were observational and only one randomised trial was 
included. However, the review does complement a 
recently published systematic review on the effective-
ness and safety of oral drugs for type 2 diabetes, which 
found that metformin and second generation sulphonyl-
ureas are similarly effective or even superior in terms 
of glycaemic effects to newer and more expensive 
agents.11
Despite the new information provided by these 
reviews, more evidence is urgently needed on the ben-
efits of newer antidiabetic drugs in different populations 
of patients. Future trials should not only include clinical 
end points, but also outcomes that are important to 
patients, in line with the draft guidance from the US 
Food and Drug Administration.12 Patients are experts 
on their own quality of life. It would seem wise therefore 
for the medical industry and scientists to ask patients to 
join them in designing clinical trials and choosing the 
most relevant outcomes to be reported by patients.
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Mild hypothermia for post cardiac arrest syndrome
Is recommended by evidence based guidelines yet uptake remains poor
Most people who have a cardiac arrest die. Many who 
are resuscitated subsequently die over the next few 
hours or days, and those who survive are at risk of cog-
nitive dysfunction. This gloomy reality has prompted 
research into interventions to improve the prognosis of 
cardiac arrest; one of these interventions is the induc-
tion of mild hypothermia after spontaneous circulation 
has been restored.
Apart from patients resuscitated from a very brief 
cardiac arrest, most survivors will be comatose initially, 
and those without extensive comorbidity will be admit-
ted to an intensive care unit. Unconscious, mechani-
cally ventilated survivors of cardiac arrest account for 
one in 17 of all admissions to intensive care in the 
United Kingdom.1 A third of these patients survive to 
hospital discharge. In one centre, two thirds of deaths 
in intensive care in initial survivors of cardiac arrest 
that occurred out of hospital, and a quarter of deaths 
after cardiac arrest that occurred in hospital, were 
attributed primarily to a neurological cause.2
Organ injury caused by ischaemia and hypoxia 
during prolonged cardiac arrest is compounded by 
reperfusion injury that occurs when a spontaneous 
circulation is restored. These insults trigger a systemic 
inflammatory response, similar to that associated 
with sepsis.3 The term post cardiac arrest syndrome 
describes this systemic response and associated multi-
ple organ dysfunction.
Mild hypothermia is neuroprotective both before 
and after brain ischaemia through several mechanisms, 
including reduced production of excitotoxins and free 
radicals, suppression of apoptosis, and other anti-
inflammatory actions.4 Animal studies show that hypo-
thermia is more effective the earlier it is started after 
return of spontaneous circulation. Two randomised but 
unblinded clinical trials5 6 and a meta-analysis7 show 
improved survival and neurological outcome in adults 
who remained comatose after initial resuscitation from 
out of hospital ventricular fibrillation cardiac arrest, 
and who were cooled within minutes to hours after 
initial resuscitation. Patients were cooled to 33ºC6 or to 
32-34ºC for 12-24 hours.5 Between four and 13 patients 
need to be treated for one extra survivor to leave hos-
pital with good neurological function.7 None of the 
studies showed an increase in the number of survivors 
with poor neurological function.
Contraindications to inducing mild hypother-
mia include severe systemic infection, pre-existing 
coagulopathy (previous thrombolytic therapy is not 
a contraindication), and established multiple organ 
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failure. Complications of mild hypothermia include 
increased infection, cardiovascular instability, coagu-
lopathy, hyperglycaemia, increased plasma amylase, 
hypophosphataemia, and hypomagnesaemia.8 Most of 
these complications are easy to treat in the intensive 
care unit or can be reduced by raising the patient’s tem-
perature slowly by 1-2oC.
Despite the evidence and inclusion in guidelines, 
the uptake of mild hypothermia by intensive care units 
around the world is poor.9 Some clinicians remain 
sceptical about the evidence—just two relatively small 
unblinded controlled trials; one used pseudorandomisa-
tion to allocate treatments,6 the other enrolled just 8% of 
all the patients assessed for eligibility.5
It is still not clear whether patients outside of the inclu-
sion criteria used in the original trials would benefit from 
hypothermia (such as those with cardiac arrests occur-
ring in hospital or non-ventricular fibrillation cardiac 
arrests). A randomised trial of hypothermia after resus-
citation following in hospital cardiac arrest is ongoing 
(ClinicalTrials.gov identifier NCT00457431).
An effective and easy method to initiate cooling is 
rapid infusion of cold (4°C) intravenous fluid.10 Cool-
ing should start as soon as possible. This means that 
for cardiac arrests occurring out of hospital, cooling 
should ideally be started at the scene of the arrest or in 
the ambulance or, at the very latest, in the emergency 
department. A randomised controlled trial assessing 
long term survival after prehospital induction of hypo-
thermia with cold intravenous fluid is about to start 
(ClinicalTrials.gov identifier NCT00391469).
No consensus exists on the best way to maintain hypo-
thermia, the optimum duration for hypothermia, or how 
best to rewarm the patient. In our experience, simple 
methods to maintain hypothermia—such as surface cool-
ing with icepacks and fans—can work, but over-cooling 
and under-cooling are common. Intravascular cooling 
methods enable tighter temperature control, but inser-
tion of large bore intravascular catheters has risks and 
the disposables are expensive.
Mild hypothermia is just one component of treatment 
for the post cardiac arrest syndrome. Other important 
components include early coronary reperfusion (per-
cutaneous intervention or thrombolysis), controlled 
ventilation to achieve normal arterial blood oxygen 
and carbon dioxide tensions, cardiovascular support 
with vasoactive drugs, and, if necessary, an intra-aortic 
balloon pump, and intensive control of blood glucose. 
Evidence suggests that implementing a systematic treat-
ment protocol after resuscitation improves outcomes.11
Current guidelines recommend that unconscious 
adults with spontaneous circulation after out of hospital 
cardiac arrest should be cooled to 32-34ºC for 12-24 
hours when the initial rhythm was ventricular fibrilla-
tion.12 This treatment may be considered for uncon-
scious adult patients with spontaneous circulation after 
out of hospital cardiac arrest with any other rhythm 
or after in hospital cardiac arrest. Many intensive care 
doctors, including ourselves, now cool most comatose 
patients admitted to intensive care after cardiac arrest.
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The recent flurry of criminal cases brought against 
people in the United Kingdom accused of infecting 
their sexual partner(s) with HIV has resulted in several 
convictions. This has caused concern among health 
professionals and community groups about the det-
rimental effect such cases may have on disclosure of 
HIV infection and uptake of voluntary HIV testing, 
which contrasts with the move to normalise HIV test-
ing and clinical care. The potential negative effect of 
this on the public health programme to reduce trans-
mission of HIV has been widely discussed in these 
pages1 2 and elsewhere.3
Virological evidence, specifically HIV gene 
sequence data obtained from the defendant and com-
plainant, has been used in these cases because a pre-
requisite for establishing criminal liability is that the 
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defendant caused the complainant’s infection. Because 
HIV-1, like other RNA viruses, evolves rapidly, the 
virus isolated from independently infected people is 
typically distinct. The extent of similarity between 
viruses from different people is associated with the 
likelihood of a common source of infection.
Within infected people, viral populations expand 
from a small initial population, and the viral genome 
can change during chronic infection by up to 1% each 
year. Thus, an onward transmission, if it occurred 
some time after initial infection, is likely to involve a 
strain distinguishable from the host viral strain. Viral 
phylogenetics, the scientific study of evolutionary 
relations between strains, has previously been used 
successfully to explore occupational and healthcare 
related transmissions in the context of detailed epide-
miological information in cases in Florida,4 Baltimore,5 
and Louisiana.6
In recent criminal cases in the UK, attempts have 
been made to present evidence on the viral sequence 
as a conceptual framework akin to DNA fingerprint-
ing (for which the odds of DNA samples from two 
different people being the same is typically lower than 
the population of the planet). In our view, this analogy 
is seriously misleading for several reasons, and when 
attempting to establish that transmission occurred 
between specific people virological evidence should 
be used with caution and only in conjunction with the 
clinical and epidemiological evidence.
Viral phylogenetics provides methods for assessing 
the relations between viruses from different people. 
A phylogeny is a hypothesis under which we can esti-
mate the probability that viruses from two particular 
people have a recent common origin, but only in rela-
tion to other strains compared. The reliability of the 
conclusion depends both on the assumptions made 
in the statistical analysis and the data available for 
analysis.
Statistical tests (parametric, non-parametric, or 
Bayesian) are used to evaluate one such hypothesis 
against another, but if an inaccurate model is speci-
fied, or if the most relevant data are not included, 
these tests can, perhaps counterintuitively, give formal 
support to an incorrect conclusion. There are serious 
limitations on what can and cannot be inferred using 
phylogenetics alone and, in our view, a conviction that 
relies on such evidence to establish transmission is 
inherently unsafe. For these reasons, expertise should 
be sought before undertaking such analyses.7-9
The greatest difficulty lies with the nature of the 
data. Identifying a linkage between viruses from 
two people on its own says nothing about the direc-
tion of transmission (who infected whom?) without 
allied information for the individuals concerned, and 
multiple specimens may be needed from before and 
after infection. Secondly, it is unlikely that all sexual 
contacts of all HIV infected people will be available 
for viral testing; indeed some may not be diagnosed. 
Thus, it is extremely difficult to distinguish a direct 
transmission between two people from a transmis-
sion from a third party to both, or from the first to 
the second person indirectly through a third. Thirdly, 
because HIV infected people can be coinfected or 
superinfected with genetically diverse strains, interpre-
tation of the phylogeny is even more complex. Finally, 
similarities in two virus genomes may occur as a result 
of convergent or parallel evolution. An example of 
such is the independent development of drug resist-
ance mutations, which can erroneously link people 
with no history of direct contact.10 Now that this is 
known, genetic positions subject to mutation associ-
ated with drug resistance can be excluded, but other 
sources of convergent evolution, such as those that 
might be produced by the virus evolving to escape the 
immune system, are not as well characterised.
We therefore advise caution when interpreting such 
data because the strength of any apparent linkage 
between viruses will never approach the degree of 
certainty generally expected of “DNA” data in a 
criminal court, which juries are more familiar with. 
Phylogenetic evidence—together with clinical and 
epidemiological evidence regarding likely duration 
of infection, sexual history, and other relevant fac-
tors—can provide support for linkage between cases 
but cannot prove transmission.
In this context, the only safe use of virus gene 
sequences is in circumstances where the genetic dif-
ferences between viruses are sufficient to make linkage 
between two people doubtful (or in the case of differ-
ent HIV-1 subtypes, highly unlikely). This is equiva-
lent to the ability of blood grouping to establish that 
two samples come from different people (when the 
blood group differs), but not that they come from the 
same person (when the blood group is the same).
Despite the difficulty in determining linkage between 
specific individuals, phylogenetics can provide impor-
tant new insights in investigations. A recent example 
is a study of the timing of HIV-1 infections among 
Libyan children in hospital, which showed that most 
infections occurred before the arrival of the accused 
medical workers in the country.11 Within the UK, new 
diagnoses comprise imported infections, many from 
sub-Saharan Africa, together with a growing number 
of infections acquired within the UK, overwhelmingly 
in men who have sex with men. The speed with which 
imported infections, from Eastern Europe as well as 
Africa, will lead to ongoing spread within the UK is 
unknown, as is the future mixing of viruses between 
different risk groups (those practising heterosexual or 
homosexual sex).
Molecular epidemiological approaches, allied to 
existing surveillance of HIV, will allow sensitive real 
time monitoring of such trends to be established, 
thus guiding targeted and cost effective public health 
 interventions.
It will be important that sufficient checks and bal-
ances are in place to allow full use of such data for 
public health benefit, without concern that the under-
lying purpose for identifying possible viral genetic 
linkage between people will be to support criminal 
proceedings.
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Efforts are increasing to ensure that resource poor 
countries, which bear almost 90% of the global disease 
burden, have access to effective medicines.1 As a result, 
drug companies are facing increased pressure from gov-
ernments, the World Health Organization, and patient 
lobby groups to remove legal and financial barriers to 
access.2 However, although these campaigns are neces-
sary and clearly laudable, they are not accompanied by 
the development or upscaling of processes for moni-
toring drug safety. Although many drugs have been 
extensively used and studied in developed countries 
(thus informing global practice), their safety profile can-
not necessarily be generalised to developing countries, 
where the incidence, pattern, and severity of adverse 
reactions may differ markedly because of local environ-
mental and genetic influences.3
After the thalidomide disaster in the 1960s, most 
Western countries developed national pharmacovigi-
lance systems.4 These systems use spontaneous report-
ing or other pharmacoepidemiological methods to 
systematically collect and analyse adverse events asso-
ciated with the use of drugs, identify signals or emerg-
ing problems, and communicate how to minimise or 
prevent harm. Although these processes are not perfect, 
as exemplified by recent problems,5 they do provide 
evidence that can be used to institute regulatory action 
to protect public health.
At the global level, the WHO programme for inter-
national drug monitoring at the Uppsala Monitoring 
Centre collates adverse drug reaction reports via the 
national pharmacovigilance centres of the 81 member 
countries (www.who-umc.org). However, currently 
only six sub-Saharan African countries (South Africa, 
Zimbabwe, Tanzania, Mozambique, Nigeria, and 
Ghana) are full members of the programme. In fact, 
less than 27% of lower middle income and low income 
economies have national pharmacovigilance systems 
registered with the WHO programme, compared with 
96% of the high income countries in the Organisation 
for Economic Co-operation and Development. The 
main reasons for this are lack of resources, infrastruc-
ture, and expertise. Thus, although access to medicines 
is increasing in developing countries, there is a danger 
that their risk benefit profiles in indigenous populations 
will not be fully monitored and acted upon.
So what can be done to improve drug safety monitor-
ing in developing countries? In the short term, we need 
to make better use of ongoing or planned studies. The 
ability to detect an adverse drug reaction depends on 
its frequency and the total number of people exposed 
to the drug.6 A logical approach would be to encour-
age collaboration between academic investigators, 
drug companies, and governments undertaking clinical 
studies to develop common adverse reaction reporting 
forms and to deposit the data into a single database.
Similar partnerships could also be established with 
organisers of public health and drug access campaigns 
and with regional surveillance systems, such as the East 
African network for monitoring antimalarial treatment7 
and the network for assessing health and demography 
in developing countries.8 The operational advantages 
of this approach are that data can be obtained from a 
range of studies and that pre-existing manual and tech-
nical infrastructures can be used to acquire the data. 
This would provide demographically relevant data from 
large (and less homogeneous) populations in a struc-
tured and systematic fashion, and these data could then 
be used to identify warning signals.
Individual investigators would still own their data and 
publish results of their trials, but the pooling of data 
on adverse drug reactions would add value to ongoing 
studies. This has already happened on a small scale. 
For example, an increased risk of serious neurological 
reactions was identified in people taking ivermectin who 
were infected with Loa loa before treatment started.9 
Such pooling of data needs to be increased and consid-
ered for all drug classes within a formulary.
What role should the drug industry have in promoting 
pharmacovigilance? The current model for drug devel-
opment in resource poor settings depends on public-
private partnerships, such as the Medicines for Malaria 
Venture. These partnerships should be encouraged to 
continue beyond the point of obtaining a drug licence 
to developing a proactive phase IV programme. Such a 
programme could be designed to show the effectiveness 
of the drug in a real world situation, and through this 
obtain safety data in much larger cohorts of patients. A 
few examples of this approach already exist in Africa,10 
but these need to become the norm rather than the 
exception.
In the long term, every country should develop its 
own national pharmacovigilance system, which con-
tributes to a global database such as that held by the 
Uppsala Monitoring Centre. This will need an extensive 
infrastructure, however, which would be costly. In a 
climate where health resources are limited, funding a 
pharmacovigilance system will come second to other 
competing priorities such as implementing a new vac-
cine programme. The funding model for pharmacovigi-
lance activities in the United States recently advocated 
by the Institute of Medicine11 is unlikely to work in 
developing countries if it increases drug costs, as this 
defeats the aim of increasing access to medicines. No 
easy answers are available, but WHO needs to lead 
a dialogue between the major stakeholders with the 
aim of developing a novel funding model that supports 
pharmacovigilance activities in developing countries. 
The lack of local expertise in pharmacovigilance could 
be tackled through developing exchange programmes 
with the major drug regulatory agencies and sharing of 
best practices.
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